JP7779739B2 - 認知障害を処置するためのパルス状ｇｎｒｈ投与 - Google Patents

認知障害を処置するためのパルス状ｇｎｒｈ投与

Info

Publication number
JP7779739B2
JP7779739B2 JP2021564303A JP2021564303A JP7779739B2 JP 7779739 B2 JP7779739 B2 JP 7779739B2 JP 2021564303 A JP2021564303 A JP 2021564303A JP 2021564303 A JP2021564303 A JP 2021564303A JP 7779739 B2 JP7779739 B2 JP 7779739B2
Authority
JP
Japan
Prior art keywords
gnrh
mice
ts65dn
cognitive
olfactory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533011A (ja
JP2022533011A5 (https=
Inventor
プレヴォ，ヴァンサン
メッシーナ，アンドレア
ジャコビニ，パオロ
レイセン，ヴァレリー
マンフレディ・ロザーノ，マリア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre Hospitalier Universitaire de Lille
Universite de Lille
Original Assignee
Centre Hospitalier Universitaire de Lille
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Universitaire de Lille, Universite de Lille filed Critical Centre Hospitalier Universitaire de Lille
Publication of JP2022533011A publication Critical patent/JP2022533011A/ja
Publication of JP2022533011A5 publication Critical patent/JP2022533011A5/ja
Application granted granted Critical
Publication of JP7779739B2 publication Critical patent/JP7779739B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021564303A 2019-04-30 2020-04-29 認知障害を処置するためのパルス状ｇｎｒｈ投与 Active JP7779739B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305550.6 2019-04-30
EP19305550 2019-04-30
PCT/EP2020/061943 WO2020221821A1 (en) 2019-04-30 2020-04-29 Pulsative gnrh administration for treating cognitive disorders

Publications (3)

Publication Number Publication Date
JP2022533011A JP2022533011A (ja) 2022-07-21
JP2022533011A5 JP2022533011A5 (https=) 2023-05-11
JP7779739B2 true JP7779739B2 (ja) 2025-12-03

Family

ID=66625872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564303A Active JP7779739B2 (ja) 2019-04-30 2020-04-29 認知障害を処置するためのパルス状ｇｎｒｈ投与

Country Status (5)

Country Link
US (1) US20220202895A1 (https=)
EP (1) EP3962494B1 (https=)
JP (1) JP7779739B2 (https=)
DK (1) DK3962494T3 (https=)
WO (1) WO2020221821A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022136417A1 (en) 2020-12-22 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Pulsative gnrh administration for treating food intake related disorders
WO2024047115A1 (en) 2022-09-02 2024-03-07 Leibniz-Institut Für Immuntherapie (Lit) THERAPEUTIC USE OF THE miR155 SNP rs377265631

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041386A2 (en) 2005-09-30 2007-04-12 Vyteris, Inc. Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch
WO2014179139A2 (en) 2013-04-30 2014-11-06 Albert Einstein College Of Medicine Of Yeshiva University TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION
WO2017182580A1 (en) 2016-04-20 2017-10-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3474412D1 (en) 1984-04-14 1988-11-10 Ferring Biotechnik Device for the intermittent delivery of medicaments
US5013293A (en) 1987-05-28 1991-05-07 Drug Delivery Systems Inc. Pulsating transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
US20080171736A1 (en) * 2004-12-23 2008-07-17 Gregory Christopher W Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists
WO2014110549A1 (en) * 2013-01-14 2014-07-17 The General Hospital Corporation Methods and assays relating to rnf216
CN108837143B (zh) * 2018-09-29 2022-03-01 南华大学 曲普瑞林的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007041386A2 (en) 2005-09-30 2007-04-12 Vyteris, Inc. Pulsatile delivery of gonadotropin-releasing hormone from a pre-loaded integrated electrotransport patch
WO2014179139A2 (en) 2013-04-30 2014-11-06 Albert Einstein College Of Medicine Of Yeshiva University TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK-β/NF-κΒ INHIBITION
WO2017182580A1 (en) 2016-04-20 2017-10-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The olfactory system and its disorders，Semin Neurol.，2009年，Vol. 29, No. 1，p. 74-81，doi: 10.1055/s-0028-1124025
ゴナドトロピンサブユニット遺伝子発現調節機構に関する研究，日本下垂体研究会誌，2016年，第３号，1-5

Also Published As

Publication number Publication date
JP2022533011A (ja) 2022-07-21
US20220202895A1 (en) 2022-06-30
WO2020221821A1 (en) 2020-11-05
DK3962494T3 (da) 2026-04-07
EP3962494B1 (en) 2026-03-04
EP3962494A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
Malone et al. Defective AMH signaling disrupts GnRH neuron development and function and contributes to hypogonadotropic hypogonadism
Messina et al. A microRNA switch regulates the rise in hypothalamic GnRH production before puberty
Bomfim et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers
Yu et al. A role for CIM6P/IGF2 receptor in memory consolidation and enhancement
Díaz-Moreno et al. Aβ increases neural stem cell activity in senescence-accelerated SAMP8 mice
Chen et al. Increasing astrogenesis in the developing hippocampus induces autistic‐like behavior in mice via enhancing inhibitory synaptic transmission
Hoy et al. Neuroligin1 drives synaptic and behavioral maturation through intracellular interactions
Jensen et al. Targeting TNFα produced by astrocytes expressing amyotrophic lateral sclerosis‐linked mutant fused in sarcoma prevents neurodegeneration and motor dysfunction in mice
JP7779739B2 (ja) 認知障害を処置するためのパルス状ｇｎｒｈ投与
EP3701499A1 (en) Treatment for skeletal diseases caused by intracellular protein trafficking defects
JP7122002B2 (ja) 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
WO2017182580A1 (en) Methods for the diagnosis and the treatment of reproduction-related disorders and methods for contraception
WO2016201086A1 (en) Compositions and methods for stimulating adam10-mediated nonamyloidogenic proteolysis of amyloid precursor protein
Howard Mineralocorticoid and Glucocorticoid Signaling Differently Affect Skeletal Muscle Inflammation in Muscular Dystrophy
Vandal et al. The Alzheimer risk factor CD2AP causes dysfunction of the brain vascular network
de Moura Oliveira Neural mechanisms of female aggression: Implications on the oxytocin and vasopressin systems
Leysen The role of GnRH in the age-related cognitive decline in some disorders including Down syndrome
Abed The Role of Transcription Factors in RGC Development, Maintenance, and Survival
Abed The Role of Transcription Factors in Retinal Ganglion Cell Development, Maintenance, and Survival
De Guzman Alterations in Corticotropin-Releasing Factor Receptor Type 1 in the Hypothalamus and Preoptic Area During the Postpartum Period
Yang et al. NLRP6 governs hippocampal microglial phagocytosis to resist stress-induced depressive-like behaviors in mice and the intervention effect of bezafibrate
Holden Benefits and risks of childhood immunisations in developing countries.
US20200282210A1 (en) Methods of Generating Mature Human Muscle Fibers
Eltokhi Dissecting hormonal and transient effects in Shankopathies associated with autism spectrum disorder
US20240034765A1 (en) Scg2 neuropeptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251104

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251120

R150 Certificate of patent or registration of utility model

Ref document number: 7779739

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150